0000000000437840

AUTHOR

Michael Kalos

showing 4 related works from this author

T cell assays and MIATA: the essential minimum for maximum impact.

2012

The Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA*Correspondence: cedrik.britten@tron-mainz.dehttp://dx.doi.org/10.1016/j.immuni.2012.07.010The field of immunology has recentlyexperienced enormous advances fromwhich most have so far not been incorpo-rated into standard medical practice (Da-vis, 2008). One approach to fully exploitthe existing wealth of knowledge is toimplement a systematic strategy to eval-uate the immune system. The potentialbenefit of such an approach is that itmay lead to results that can be translatedinto the rational development of diagnos-tics and therapeutics (Hoos et al., 2011).Two prerequisites for its application ar…

Immunoassay0303 health sciencesT-LymphocytesImmunologyMedical practiceBiologyData science3. Good health03 medical and health sciences0302 clinical medicineInfectious Diseases030220 oncology & carcinogenesisImmunologyImmunology and AllergyHumans030304 developmental biologyImmunity
researchProduct

The role of the reporting framework MIATA within current efforts to advance immune monitoring

2014

Quality Controlmedicine.medical_specialtyLaboratory Proficiency TestingConsensusmedicine.medical_treatmentInternational CooperationT-LymphocytesImmunologyImmune monitoringPharmacologyImmunologic TestsImmune assaysMonitoring ImmunologicPredictive Value of TestsmedicineImmunology and AllergyHumansCooperative BehaviorIntensive care medicineImmune monitoringObserver Variationbusiness.industryGuideline adherenceMIATAImmunologic TestsReproducibility of ResultsImmunotherapyTreatment OutcomeReportingPredictive value of testsPractice Guidelines as TopicCooperative behaviorLaboratory Proficiency TestingGuideline AdherenceImmunotherapyCurrent (fluid)businessLaboratories
researchProduct

“MIATA”—Minimal Information about T Cell Assays

2009

Immunotherapy, especially therapeutic vaccination, has a great deal of potential in the treatment of cancer and certain infectious diseases such as HIV (Allison et al., 2006; Fauci et al., 2008; Feldmann and Steinman, 2005). Numerous vaccine candidates have been tested in patients with a variety of tumor types and chronic viral diseases. Often, the best way to assess the clinical potential of these vaccines is to monitor the induced T cell response, and yet there are currently no standards for reporting these results. This letter is an effort to address this problem.

T-LymphocytesT cellmedicine.medical_treatmentImmunologyHuman immunodeficiency virus (HIV)medicine.disease_causeT cell responseCancer VaccinesArticleMonitoring ImmunologicNeoplasmsmedicineHumansImmunology and AllergyIn patientImmunoassaybusiness.industryViral VaccineCancerViral VaccinesImmunotherapymedicine.diseaseVaccinationInfectious Diseasesmedicine.anatomical_structureVirus DiseasesPractice Guidelines as TopicImmunologyImmunotherapybusinessCancer Vaccines/immunology; Cancer Vaccines/therapeutic use; Humans; Immunoassay/standards; Immunotherapy; Monitoring Immunologic/standards; Neoplasms/therapy; Practice Guidelines as Topic/standards; T-Lymphocytes/immunology; Viral Vaccines/immunology; Viral Vaccines/therapeutic use; Virus Diseases/therapyImmunity
researchProduct

Harmonization of Immune Biomarker Assays for Clinical Studies

2011

Assays that measure a patient's immune response play an increasingly important role in the development of immunotherapies. The inherent complexity of these assays and independent protocol development between laboratories result in high data variability and poor reproducibility. Quality control through harmonization--based on integration of laboratory-specific protocols with standard operating procedures and assay performance benchmarks--is one way to overcome these limitations. Harmonization guidelines can be widely implemented to address assay performance variables. This process enables objective interpretation and comparison of data across clinical trial sites and also facilitates the ide…

Protocol (science)ImmunoassayClinical Trials as TopicData variabilitybusiness.industryOperating proceduresHarmonizationGeneral MedicineComputational biologyBioinformaticsClinical trialImmune systemBiomarker (medicine)MedicineHumansbusinessBiomarkers
researchProduct